| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.375 | 0.004 | 0.733 | Phosphodiesterase IV inhibitor | 0.48 0.004 DBMET03249 0.435 0.004 DBMET03250 0.733 0.003 DBMET03251 | DBMET03251 | |
| 0.406 | 0.063 | 0.5 | Antiobesity | 0.387 0.071 DBMET03249 0.482 0.041 DBMET03250 0.5 0.037 DBMET03251 | DBMET03251 | |
| 0.341 | 0.003 | 0.364 | Lysine-specific demethylase 1A inhibitor | 0.168 0.004 DBMET03249 0.364 0.003 DBMET03250 0.09 0.009 DBMET03251 | DBMET03250 | |
| 0.371 | 0.033 | 0.371 | HERG channel blocker | 0.289 0.052 DBMET03249 0.356 0.036 DBMET03250 0.315 0.045 DBMET03251 | ||
| 0.415 | 0.083 | 0.429 | Cyclophilin D inhibitor | 0.387 0.098 DBMET03249 0.429 0.076 DBMET03250 | DBMET03250 | |
| 0.325 | 0.024 | 0.363 | Interleukin-1 receptor-associated protein kinase 1 inhibitor | 0.327 0.024 DBMET03249 0.363 0.016 DBMET03250 0.248 0.049 DBMET03251 | DBMET03250 | |
| 0.364 | 0.075 | 0.451 | Toll-Like receptor 7 agonist | 0.398 0.061 DBMET03249 0.364 0.075 DBMET03250 0.451 0.043 DBMET03251 | DBMET03251 | |
| 0.364 | 0.075 | 0.448 | Toll-Like receptor agonist | 0.397 0.061 DBMET03249 0.363 0.076 DBMET03250 0.448 0.044 DBMET03251 | DBMET03251 | |
| 0.327 | 0.042 | 0.327 | Potassium channel (Voltage-sensitive) blocker | 0.254 0.065 DBMET03249 0.313 0.045 DBMET03250 0.262 0.062 DBMET03251 | ||
| 0.306 | 0.044 | 0.306 | Potassium channel blocker | 0.257 0.063 DBMET03249 0.285 0.052 DBMET03250 0.234 0.074 DBMET03251 | ||
| 0.279 | 0.017 | 0.375 | Phosphodiesterase inhibitor | 0.338 0.011 DBMET03249 0.271 0.019 DBMET03250 0.375 0.008 DBMET03251 | DBMET03251 | |
| 0.266 | 0.012 | 0.266 | Toll-Like receptor antagonist | 0.121 0.082 DBMET03249 0.237 0.019 DBMET03250 | ||
| 0.255 | 0.005 | 0.256 | Hepatocyte growth factor antagonist | 0.239 0.006 DBMET03249 0.256 0.005 DBMET03250 0.215 0.009 DBMET03251 | DBMET03250 | |
| 0.253 | 0.005 | 0.375 | Phosphodiesterase 4B inhibitor | 0.375 0.004 DBMET03249 0.29 0.005 DBMET03250 0.07 0.044 DBMET03251 | DBMET03249 | |
| 0.209 | 0.01 | 0.225 | Phosphodiesterase 4D inhibitor | 0.225 0.009 DBMET03249 0.213 0.01 DBMET03250 0.146 0.02 DBMET03251 | DBMET03249 | |
| 0.181 | 0.013 | 0.22 | Interleukin-1 receptor-associated protein kinase 4 inhibitor | 0.186 0.012 DBMET03249 0.22 0.007 DBMET03250 0.099 0.046 DBMET03251 | DBMET03250 | |
| 0.193 | 0.032 | 0.276 | Sodium channel (voltage-gated) blocker | 0.198 0.03 DBMET03249 0.213 0.025 DBMET03250 0.276 0.011 DBMET03251 | DBMET03251 | |
| 0.224 | 0.068 | 0.284 | Anticonvulsant | 0.284 0.045 DBMET03249 0.177 0.101 DBMET03250 | DBMET03249 | |
| 0.189 | 0.036 | 0.255 | Sodium channel blocker | 0.177 0.042 DBMET03249 0.194 0.035 DBMET03250 0.255 0.017 DBMET03251 | DBMET03251 | |
| 0.187 | 0.051 | 0.187 | Growth factor antagonist | 0.139 0.077 DBMET03249 0.168 0.059 DBMET03250 0.148 0.07 DBMET03251 | ||
| 0.241 | 0.116 | 0.271 | Nootropic | 0.271 0.091 DBMET03249 0.211 0.144 DBMET03250 0.226 0.129 DBMET03251 | DBMET03249 | |
| 0.136 | 0.011 | 0.166 | Phosphodiesterase 4A inhibitor | 0.166 0.009 DBMET03249 0.137 0.011 DBMET03250 0.089 0.018 DBMET03251 | DBMET03249 | |
| 0.195 | 0.075 | 0.228 | I kappa B kinase epsilon inhibitor | 0.228 0.05 DBMET03250 | DBMET03250 | |
| 0.131 | 0.022 | 0.131 | Phosphodiesterase I inhibitor | 0.109 0.035 DBMET03249 0.09 0.058 DBMET03250 | ||
| 0.116 | 0.007 | 0.116 | Phosphodiesterase 1A inhibitor | 0.112 0.008 DBMET03249 0.073 0.021 DBMET03250 | ||
| 0.176 | 0.068 | 0.176 | Antipruritic | 0.165 0.079 DBMET03249 0.133 0.118 DBMET03250 0.151 0.093 DBMET03251 | ||
| 0.16 | 0.057 | 0.16 | Toll-Like receptor 9 antagonist | 0.106 0.103 DBMET03250 | ||
| 0.16 | 0.057 | 0.187 | Hemostatic | 0.143 0.077 DBMET03249 0.187 0.038 DBMET03250 0.149 0.07 DBMET03251 | DBMET03250 | |
| 0.108 | 0.011 | 0.108 | Melanin-concentrating hormone receptor 1 antagonist | 0.05 0.04 DBMET03249 0.074 0.022 DBMET03250 | ||
| 0.101 | 0.009 | 0.103 | Proto-oncogene tyrosine-protein kinase Met inhibitor | 0.092 0.012 DBMET03249 0.103 0.009 DBMET03250 0.07 0.021 DBMET03251 | DBMET03250 | |
| 0.1 | 0.009 | 0.109 | Toll-Like receptor 8 antagonist | 0.052 0.038 DBMET03249 0.109 0.007 DBMET03250 | DBMET03250 | |
| 0.112 | 0.022 | 0.124 | Phosphodiesterase 5A inhibitor | 0.124 0.017 DBMET03249 0.099 0.027 DBMET03250 0.113 0.021 DBMET03251 | DBMET03249 | |
| 0.123 | 0.036 | 0.123 | Uric acid excretion stimulant | 0.098 0.055 DBMET03249 0.119 0.039 DBMET03250 0.091 0.064 DBMET03251 | ||
| 0.11 | 0.023 | 0.121 | Phosphodiesterase V inhibitor | 0.121 0.018 DBMET03249 0.098 0.028 DBMET03250 0.111 0.023 DBMET03251 | DBMET03249 | |
| 0.09 | 0.007 | 0.094 | Guanylate cyclase stimulant | 0.087 0.008 DBMET03249 0.094 0.007 DBMET03250 0.069 0.011 DBMET03251 | DBMET03250 | |
| 0.211 | 0.135 | 0.241 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.241 0.078 DBMET03250 | DBMET03250 | |
| 0.12 | 0.045 | 0.299 | Bronchodilator | 0.126 0.041 DBMET03249 0.118 0.046 DBMET03250 0.299 0.009 DBMET03251 | DBMET03251 | |
| 0.098 | 0.024 | 0.118 | Nav1.7 sodium channel blocker | 0.089 0.028 DBMET03249 0.118 0.017 DBMET03250 0.114 0.018 DBMET03251 | DBMET03250 | |
| 0.085 | 0.02 | 0.085 | Phosphodiesterase 1B inhibitor | 0.076 0.025 DBMET03249 | ||
| 0.091 | 0.028 | 0.094 | Toll-Like receptor 7 antagonist | 0.058 0.057 DBMET03249 0.094 0.025 DBMET03250 | DBMET03250 | |
| 0.071 | 0.013 | 0.071 | Glutamate (mGluR5) agonist | 0.065 0.015 DBMET03249 0.046 0.031 DBMET03250 | ||
| 0.071 | 0.016 | 0.071 | Glutamate (mGluR group I) agonist | 0.066 0.018 DBMET03249 0.051 0.03 DBMET03250 | ||
| 0.086 | 0.03 | 0.137 | Phosphodiesterase III inhibitor | 0.129 0.013 DBMET03249 0.086 0.03 DBMET03250 0.137 0.012 DBMET03251 | DBMET03251 | |
| 0.096 | 0.04 | 0.109 | Glutamate receptor agonist | 0.109 0.031 DBMET03249 | DBMET03249 | |
| 0.135 | 0.08 | 0.167 | Vascular endothelial growth factor 3 antagonist | 0.167 0.056 DBMET03250 | DBMET03250 | |
| 0.244 | 0.188 | 0.458 | Analgesic | 0.246 0.186 DBMET03249 0.458 0.062 DBMET03251 | DBMET03251 | |
| 0.093 | 0.039 | 0.158 | Phosphodiesterase 3A inhibitor | 0.158 0.014 DBMET03249 0.086 0.048 DBMET03250 | DBMET03249 | |
| 0.087 | 0.033 | 0.087 | Amidase inhibitor | 0.068 0.052 DBMET03249 | ||
| 0.083 | 0.03 | 0.085 | Orexin receptor 1 antagonist | 0.085 0.027 DBMET03249 0.074 0.044 DBMET03250 | DBMET03249 | |
| 0.062 | 0.014 | 0.062 | Acetyl-CoA carboxylase inhibitor | 0.061 0.014 DBMET03249 0.061 0.014 DBMET03250 0.04 0.03 DBMET03251 | ||
| 0.058 | 0.01 | 0.058 | Phosphodiesterase 6C inhibitor | 0.056 0.012 DBMET03249 0.052 0.017 DBMET03250 0.049 0.023 DBMET03251 | ||
| 0.067 | 0.02 | 0.067 | Histamine H3 receptor antagonist | 0.053 0.025 DBMET03250 | ||
| 0.1 | 0.055 | 0.1 | Antihistaminic | 0.091 0.063 DBMET03251 | ||
| 0.135 | 0.09 | 0.247 | Cholinergic | 0.118 0.11 DBMET03249 0.247 0.029 DBMET03251 | DBMET03251 | |
| 0.108 | 0.063 | 0.122 | Granulocyte macrophage colony stimulating factor antagonist | 0.099 0.072 DBMET03250 0.122 0.052 DBMET03251 | DBMET03251 | |
| 0.07 | 0.027 | 0.079 | Phosphodiesterase 4C inhibitor | 0.079 0.022 DBMET03249 0.07 0.026 DBMET03250 | DBMET03249 | |
| 0.077 | 0.037 | 0.077 | Cannabinoid receptor agonist | |||
| 0.093 | 0.053 | 0.093 | Histamine antagonist | 0.084 0.06 DBMET03251 | ||
| 0.068 | 0.033 | 0.068 | Phosphodiesterase 1C inhibitor | 0.067 0.033 DBMET03249 | ||
| 0.274 | 0.24 | 0.274 | Antiinflammatory | 0.263 0.253 DBMET03250 | ||
| 0.072 | 0.038 | 0.073 | Orexin receptor antagonist | 0.073 0.036 DBMET03249 0.06 0.058 DBMET03250 | DBMET03249 | |
| 0.049 | 0.017 | 0.049 | Glutamate (mGluR group II) antagonist | 0.042 0.022 DBMET03249 0.04 0.025 DBMET03250 | ||
| 0.041 | 0.011 | 0.041 | Glutamate (mGluR2) antagonist | 0.035 0.015 DBMET03249 0.032 0.017 DBMET03250 | ||
| 0.04 | 0.012 | 0.04 | Phosphodiesterase 6B inhibitor | 0.036 0.015 DBMET03249 0.031 0.021 DBMET03250 | ||
| 0.082 | 0.055 | 0.099 | Acetylcholine nicotinic agonist | 0.099 0.038 DBMET03250 | DBMET03250 | |
| 0.075 | 0.049 | 0.075 | Phosphodiesterase VI inhibitor | |||
| 0.043 | 0.018 | 0.045 | Orexin receptor 2 antagonist | 0.045 0.016 DBMET03249 0.033 0.029 DBMET03250 | DBMET03249 | |
| 0.108 | 0.084 | 0.114 | Protein kinase (CK1) delta inhibitor | 0.114 0.078 DBMET03250 | DBMET03250 | |
| 0.037 | 0.013 | 0.045 | Nicotinic alpha3beta4 receptor agonist | 0.045 0.008 DBMET03250 | DBMET03250 | |
| 0.164 | 0.14 | 0.323 | Tumour necrosis factor alpha release inhibitor | 0.174 0.131 DBMET03250 0.323 0.045 DBMET03251 | DBMET03251 | |
| 0.119 | 0.097 | 0.119 | Nav1.6 sodium channel blocker | |||
| 0.059 | 0.039 | 0.059 | Fibroblast growth factor 4 antagonist | |||
| 0.03 | 0.012 | 0.03 | Acetyl-CoA carboxylase 2 inhibitor | 0.028 0.012 DBMET03249 0.03 0.012 DBMET03250 | ||
| 0.026 | 0.009 | 0.026 | Guanylate cyclase 1 stimulant | 0.024 0.009 DBMET03249 0.026 0.009 DBMET03250 0.019 0.014 DBMET03251 | ||
| 0.027 | 0.011 | 0.027 | Phosphodiesterase 6G inhibitor | 0.025 0.014 DBMET03249 0.022 0.019 DBMET03250 | ||
| 0.027 | 0.011 | 0.027 | Phosphodiesterase 6H inhibitor | 0.025 0.014 DBMET03249 0.022 0.019 DBMET03250 | ||
| 0.163 | 0.147 | 0.163 | ErbB-1 antagonist | |||
| 0.049 | 0.034 | 0.058 | Nicotinic receptor alpha4 subunit antagonist | 0.049 0.034 DBMET03249 0.058 0.023 DBMET03250 | DBMET03250 | |
| 0.057 | 0.042 | 0.057 | Adenosine A1 receptor antagonist | |||
| 0.036 | 0.022 | 0.036 | Glucose-dependent insulinotropic receptor agonist | |||
| 0.061 | 0.048 | 0.061 | Adenosine A2 receptor antagonist | |||
| 0.032 | 0.02 | 0.032 | Prostaglandin D2 agonist | 0.032 0.019 DBMET03249 0.032 0.019 DBMET03250 | ||
| 0.119 | 0.109 | 0.119 | Tyrosine kinase inhibitor | |||
| 0.024 | 0.015 | 0.024 | Phosphodiesterase 6A inhibitor | 0.022 0.02 DBMET03249 | ||
| 0.057 | 0.048 | 0.057 | Adenosine A2a receptor antagonist | |||
| 0.061 | 0.053 | 0.061 | 5 Hydroxytryptamine 3A antagonist | |||
| 0.041 | 0.035 | 0.089 | 5 Hydroxytryptamine 2C agonist | 0.089 0.009 DBMET03250 | DBMET03250 | |
| 0.029 | 0.025 | 0.029 | Potassium channel (Inward rectifier) 1 blocker | |||
| 0.05 | 0.046 | 0.066 | Nicotinic neuronal receptor agonist | 0.066 0.031 DBMET03250 | DBMET03250 | |
| 0.198 | 0.195 | 0.198 | Ca(v)3.3 blocker | |||
| 0.079 | 0.076 | 0.089 | Interleukin 5 antagonist | 0.078 0.077 DBMET03249 0.089 0.056 DBMET03250 | DBMET03250 | |
| 0.033 | 0.032 | 0.033 | G protein-coupled receptor agonist | |||
| 0.039 | 0.038 | 0.067 | Phosphodiesterase 3B inhibitor | 0.067 0.017 DBMET03249 | DBMET03249 | |
| 0.065 | 0.066 | 0.069 | Protein kinase B beta inhibitor | 0.069 0.058 DBMET03250 | DBMET03250 | |
| 0.064 | 0.068 | 0.11 | MAP-kinase-activated kinase 2 inhibitor | 0.11 0.024 DBMET03250 | DBMET03250 | |
| 0.071 | 0.076 | 0.118 | MAP-kinase-activated kinase inhibitor | 0.118 0.027 DBMET03250 | DBMET03250 | |
| 0.099 | 0.113 | 0.126 | Cytokine production inhibitor | 0.126 0.083 DBMET03250 | DBMET03250 | |
| 0.097 | 0.111 | 0.176 | Acetylcholinesterase inhibitor | 0.176 0.042 DBMET03251 | DBMET03251 | |
| 0.046 | 0.062 | 0.054 | Glutamate (mGluR) agonist | 0.054 0.051 DBMET03249 | DBMET03249 | |
| 0.095 | 0.121 | 0.104 | Sphingosine 1-phosphate receptor 2 agonist | 0.104 0.089 DBMET03250 | DBMET03250 | |
| 0.053 | 0.079 | 0.063 | Protein kinase B alpha inhibitor | 0.063 0.057 DBMET03250 | DBMET03250 | |
| 0.043 | 0.078 | 0.078 | 5 Hydroxytryptamine agonist | 0.078 0.043 DBMET03250 | DBMET03250 | |
| 0.065 | 0.103 | 0.086 | Protein kinase C delta inhibitor | 0.086 0.068 DBMET03251 | DBMET03251 | |
| 0.075 | 0.117 | 0.111 | GABA receptor agonist | 0.111 0.065 DBMET03251 | DBMET03251 | |
| 0.136 | 0.178 | 0.176 | Vasodilator | 0.176 0.126 DBMET03249 | DBMET03249 | |
| 0.064 | 0.108 | 0.123 | Check point kinase 2 inhibitor | 0.123 0.047 DBMET03250 | DBMET03250 | |
| 0.103 | 0.15 | 0.134 | CDC-like kinase 4 inhibitor | 0.134 0.114 DBMET03250 | DBMET03250 | |
| 0.071 | 0.129 | 0.186 | MAO inhibitor | 0.186 0.045 DBMET03251 | DBMET03251 | |
| 0.042 | 0.116 | 0.078 | Protein kinase (CaMK, MLCK, PhK, SNF, KIN, NIM1, MAPKAP, POLO, CHK, ULK, RSK-2nd domain) inhibitor | 0.078 0.052 DBMET03250 | DBMET03250 | |
| 0.128 | 0.207 | 0.2 | Cardiotonic | 0.2 0.119 DBMET03249 | DBMET03249 | |
| 0.048 | 0.133 | 0.08 | I kappa B kinase inhibitor | 0.08 0.061 DBMET03250 | DBMET03250 | |
| 0.055 | 0.151 | 0.105 | Polo-like kinase-4 inhibitor | 0.105 0.072 DBMET03249 | DBMET03249 | |
| 0.034 | 0.131 | 0.06 | Check point kinase 1 inhibitor | 0.06 0.059 DBMET03250 | DBMET03250 | |
| 0.022 | 0.131 | 0.044 | 5 Hydroxytryptamine 2B agonist | 0.044 0.019 DBMET03250 | DBMET03250 | |
| 0.039 | 0.153 | 0.116 | MAO A inhibitor | 0.116 0.055 DBMET03251 | DBMET03251 | |
| 0.088 | 0.204 | 0.194 | Polo-like kinase-3 inhibitor | 0.194 0.048 DBMET03251 | DBMET03251 | |
| 0.072 | 0.216 | 0.137 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.137 0.132 DBMET03250 | DBMET03250 | |
| 0.043 | 0.198 | 0.088 | Ephrin antagonist | 0.088 0.075 DBMET03251 | DBMET03251 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |